MX9701325A - Metodos para inhibir la mucositis ulcerativa. - Google Patents

Metodos para inhibir la mucositis ulcerativa.

Info

Publication number
MX9701325A
MX9701325A MX9701325A MX9701325A MX9701325A MX 9701325 A MX9701325 A MX 9701325A MX 9701325 A MX9701325 A MX 9701325A MX 9701325 A MX9701325 A MX 9701325A MX 9701325 A MX9701325 A MX 9701325A
Authority
MX
Mexico
Prior art keywords
methods
ulcerative mucositis
inhibiting
inhibiting ulcerative
mucositis
Prior art date
Application number
MX9701325A
Other languages
English (en)
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9701325A publication Critical patent/MX9701325A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion describe un método para inhibir la mucositis ulcerativa, que comprende administrar a un humano que lo necesita una cantidad efectiva de un compuesto que tiene formula I, en donde R1 y R3 son independientemente hidrogeno, -CH3, (a) o (b), en donde Ar es fenilo substituido opcionalmente; R2 se selecciona del grupo que consiste de pirrolidino, hexametilenimino, y piperidino; o una sal o solvato farmacéuticamente aceptable del mismo.
MX9701325A 1994-08-22 1995-08-21 Metodos para inhibir la mucositis ulcerativa. MX9701325A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/293,790 US5496828A (en) 1994-08-22 1994-08-22 Methods of inhibiting ulcerative mucositis
PCT/US1995/010615 WO1996005831A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting ulcerative mucositis

Publications (1)

Publication Number Publication Date
MX9701325A true MX9701325A (es) 1997-05-31

Family

ID=23130590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701325A MX9701325A (es) 1994-08-22 1995-08-21 Metodos para inhibir la mucositis ulcerativa.

Country Status (9)

Country Link
US (2) US5496828A (es)
EP (1) EP0781132A4 (es)
JP (1) JPH10504575A (es)
AU (1) AU3332495A (es)
CA (1) CA2198016A1 (es)
IL (1) IL115019A0 (es)
MX (1) MX9701325A (es)
WO (1) WO1996005831A1 (es)
ZA (1) ZA956991B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5788982A (en) * 1995-06-16 1998-08-04 Nadoolman; Wolffe Method and composition for treating oral pain using capsaicin
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CA2318471A1 (en) * 1998-01-06 1999-07-15 Alexander V. Kirichenko Nuclear scintigraphic assessment of mucosal function
US7566740B2 (en) * 1998-10-06 2009-07-28 Bml Pharmaceuticals, Inc. Method of treating mucositis
US5945089A (en) * 1998-11-05 1999-08-31 I-Dent International Corporation Method of treating mucositis
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
WO2004032843A2 (en) * 2002-10-07 2004-04-22 Orapharma, Inc. Mucoadhesive tetracycline formulations
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
ITMI20040989A1 (it) * 2004-05-18 2004-08-18 Gentium Spa Uso del sulglicotide per iul trattamento delle mucositi
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
AR053332A1 (es) * 2005-02-16 2007-05-02 Wyeth Corp Uso de agonistas selectivos para el receptor-beta de estrogeno (erp) para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair

Also Published As

Publication number Publication date
JPH10504575A (ja) 1998-05-06
IL115019A0 (en) 1995-12-08
AU3332495A (en) 1996-03-14
EP0781132A1 (en) 1997-07-02
WO1996005831A1 (en) 1996-02-29
EP0781132A4 (en) 1999-01-07
ZA956991B (en) 1997-02-20
US5496828A (en) 1996-03-05
US6274601B1 (en) 2001-08-14
CA2198016A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MY132251A (en) Methods of inhibiting cell-cell adhesion
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
PH31261A (en) Methods for inhibiting endometriosis.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
PH31596A (en) Methods of inhibiting uteine fibrosis.
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9706520A (es) Metodos para inhibir el cancer de ovario.